Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase
Regulated manufacturing, hospital field trials, and regulatory filings now underway with Ebulent Medical in ShenzhenLAS VEGAS, Jan. 15, 2026 (GLOBE…